Chuangsheng Group-B (06628) announced for the first time at the 2025 ASCO Annual Meeting the latest business progress in the new data of median survival period of Osemitamab (TST001) triple therapy for first-line treatment of gastric or gastroesophageal junction adenocarcinoma.

Zhtng Cijng APP News, Chungshng Jtun-B (06628) fb gnggo, Osemitamab (TST001) linh nwlyu dnkng h CAPOX zuwi wnq gun hu gun shgun jihb idin'i (TranStar102) yxin zhlio de y xing zhngzi jnxng de II q jngl shyn G duli gngxn ynji shj. Gi ynji jigu y bbo xngsh (zhobi binho: #4032) lingxing y zi Migu Ylnu zhu Zhjig sh jxng de 2025 nin Migu lnchung zhnglixu hu ninhu (ASCO 2025).